



#10
DD

EXPRESS MAIL NO. EV207697462US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Tongtong Wang et al.
Application No. : 09/685,696
Filed : October 9, 2000
For : COMPOUNDS AND METHODS FOR THERAPY AND
DIAGNOSIS OF LUNG CANCER
Examiner : Shin lin Chen
Art Unit : 1632
Docket No. : 210121.455C13

RECEIVED
NOV 19 2002
TECH CENTER 1600/2900

Box AF
Commissioner for Patents
Washington, DC 20231

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Form PTO-1449 (copies of the cited references, as required under 37 C.F.R. § 1.98, are enclosed). Documents on the attached Form PTO-1449 were cited in a Partial International Search Report from corresponding foreign application PCT/US01/21065, mailed October 21, 2002 (copy enclosed herewith), and in a Written Opinion from corresponding foreign application PCT/US01/47576, mailed October 11, 2002, a copy of which is not enclosed herewith. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to

11/15/2002 SLUNN51 00000018 09685696

01 FC:1806

180.00.00


the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

I hereby certify that each of the references set forth on the attached form PTO-1449 were cited in communications from a foreign patent office in counterpart foreign applications not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

Please acknowledge receipt of this Third Supplemental Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC


Julie A. Orvater, Ph.D.
Registration No. 50,461

JAU:ljt

Enclosures:

- Postcard
- Check
- Form PTO/SB/21
- Form PTO/SB/17
- Form PTO-1449
- Copies of Cited References (5)
- Copy of Partial International Search Report for PCT/US01/21065

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

EXPRESS MAIL NO. EV207697462US

FORM PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
210121.455C13

Sheet 1 of 1

APPLICATION NO.
09/685,696THIRD SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT
(On several sheets if necessary)APPLICANTS
Tongtong Wang et al.FILING DATE
October 9, 2000GROUP ART UNIT
1632

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA	5,589,579	12/31/96	Torczynski et al.	536	23.1	
AB						
AC						
AD						

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
AE WO 99/54738	10/28/99	WIPO	
AF WO 00/61612	10/19/00	WIPO	
AG			
AH			
AI			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AJ	Chen, Shen-Lin et al., "Isolation and characterization of a novel gene expressed in multiple cancers," <i>Oncogene</i> 12: 741-751, 1996.
AK	Güre, A.O. et al., "Human Lung Cancer Antigens Recognized by Autologous Antibodies: Definition of a Novel cDNA Derived from the Tumor Suppressor," <i>Cancer Research</i> 58: 1034-1041, March 1, 1998.
AL	
AM	
AN	

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).

RECEIVED
NOV 19 2002
TECH CENTER 1600/2500